Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PTPA | Q15257 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271754 | 0.90 | TP53 (0.47) | TP53ANO1PTPN1PTPRCPTPN2 | |
| SCHEMBL12271857 | 0.89 | TP53 (0.50) | TP53ANO1PTPN1PTPRCPTPN2 | |
| SCHEMBL1894867 | 0.86 | ANO1 (0.63) | ANO1MEN1KMT2A | |
| SCHEMBL1954748 | 0.86 | ANO1 (0.63) | ANO1MEN1KMT2A | |
| SCHEMBL1895978 | 0.86 | ANO1 (0.63) | ANO1MEN1KMT2A | |
| SCHEMBL1899342 | 0.86 | ANO1 (0.46) | TP53ANO1PTPN1PTPRCPTPN2 | |
| SCHEMBL1899344 | 0.82 | ANO1 (0.58) | ANO1MEN1KMT2A | |
| SCHEMBL1899340 | 0.82 | ANO1 (0.58) | ANO1MEN1KMT2A | |
| SCHEMBL12272022 | 0.81 | TP53 (0.51) | TP53ANO1PTPN1PTPRCPTPN2 | |
| SCHEMBL7950646 | 0.81 | TP53 (0.51) | TP53ANO1PTPN1PTPRCPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8383670-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383670-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7906553-B2 | Substituted thiophene modulators of intracellular calcium | CALCIMEDICA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906553-B2 | Substituted thiophene modulators of intracellular calcium | CALCIMEDICA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010027875-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TP53 2681/4885ANO1 114/4885PTPN1 3156/4885 |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TP53 2681/4885ANO1 114/4885PTPN1 3156/4885 |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | TP53 2681/4885ANO1 114/4885PTPN1 3156/4885 |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TP53 2681/4885ANO1 114/4885PTPN1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.